Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.68 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextroamphetamine SCHEMBL11760798 | 1.00 | TAAR1 (0.68) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| Amphetamine SCHEMBL8634580 | 0.93 | TAAR1 (0.73) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| Levamfetamine SCHEMBL122964 | 0.93 | TAAR1 (0.73) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| SCHEMBL7605127 | 0.86 | MAPT (0.56) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| SCHEMBL7605125 | 0.86 | MAPT (0.56) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| Amphetamine SCHEMBL2323193 | 0.85 | TAAR1 (0.73) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| Amphetamine SCHEMBL579073 | 0.85 | TAAR1 (0.73) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| Amphetamine SCHEMBL8589685 | 0.85 | TAAR1 (0.79) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| Amphetamine SCHEMBL157108 | 0.85 | TAAR1 (0.79) | TAAR1SLC6A4SLC6A2SLC6A3MAOA | |
| Amphetamine SCHEMBL29102157 | 0.85 | TAAR1 (0.79) | TAAR1SLC6A4SLC6A2SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10722562-B2 | Combinatorial analysis and repair | IMMUDEX APS (DK) | 2020-07-28 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007041571-A1 | IMPROVED METHOD OF MAKING AMPHETAMINE FREE BASE | CAMBREX CHARLES CITY, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-4293562-A | Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine | RITTER ARNOLD | 1981-10-06 | — | — | US | disclosed |
| US-4049791-A | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents | DELCO CHEMICAL COMPANY, INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-4049791-A | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents | DELCO CHEMICAL COMPANY, INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-4049791-A | Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents | DELCO CHEMICAL COMPANY, INC. (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | SMURF1, SGMS1, SMURF2 | SLC6A2 1401/4885SLC6A3 3573/4885TAAR1 3816/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | SLC6A2 1304/4885SLC6A3 2669/4885TAAR1 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.